Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.37 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.32 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | F3 | P13726 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664964 | 1.00 | HTR2A (0.38) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL12533697 | 0.89 | SRC (0.36) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL7659924 | 0.79 | PARP10 (0.39) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL8644587 | 0.76 | HTR2C (0.38) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL10242614 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL4624962 | 0.76 | DRD2 (0.37) | PARP10PARP1PARP11PNMTKDM1A | |
| SCHEMBL15813948 | 0.74 | PARP10 (0.47) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL12533705 | 0.74 | MAPT (0.47) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL26656329 | 0.73 | PNMT (0.38) | PARP10PARP1PARP11PNMTKDM1A | |
| SCHEMBL652655 | 0.71 | PARP10 (0.43) | HTR2AHTR2CHTR2BPARP10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4526289-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119546574-A | Antiviral indolinyl compounds and uses thereof | 吉利德科学公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2023225162-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225162-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-6413971-B1 | ANTIPROLIFERATIVE, -CARCINOGENIC, -TUMOR AND -DIABETIC AGENTS; BINDING TO OR MODULATING THE HUMAN KINASE INSERT-DOMAIN-CONTAINING RECEPTOR (KDR) OR THE MURINE FETAL LIVER KINASE 1 (FLK-1) RECEPTOR; VASCULOGENESIS; ANGIOGENESIS | PFIZER INC | 2002-07-02 | — | — | US | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | ARNOLD LEE DANIEL (US) | 2002-04-18 | — | — | US | disclosed |
| CN-1237177-A | Fused bicyclic pyrimidine derivatives | PFIZER (US) | 1999-12-01 | — | — | CN | disclosed |
| EP-0946554-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998023613-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| CN-1141633-A | 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | REV1, DPYD, CCNA1 | HTR2A 3781/4885HTR2C 3204/4885HTR2B 3995/4885 |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | MAVS, IRF3, EIF2AK2 | HTR2A 1990/4885HTR2C 2189/4885HTR2B 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.